首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Interpretation of the Epigenetic Signature of Facioscapulohumeral Muscular Dystrophy in Light of Genotype-Phenotype Studies
【2h】

Interpretation of the Epigenetic Signature of Facioscapulohumeral Muscular Dystrophy in Light of Genotype-Phenotype Studies

机译:基因型-表型研究解释面肩肱型肌营养不良症的表观遗传特征。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Facioscapulohumeral muscular dystrophy (FSHD) is characterized by incomplete penetrance and intra-familial clinical variability. The disease has been associated with the genetic and epigenetic features of the D4Z4 repetitive elements at 4q35. Recently, D4Z4 hypomethylation has been proposed as a reliable marker in the FSHD diagnosis. We exploited the Italian Registry for FSHD, in which FSHD families are classified using the Clinical Comprehensive Evaluation Form (CCEF). A total of 122 index cases showing a classical FSHD phenotype (CCEF, category A) and 110 relatives were selected to test with the receiver operating characteristic (ROC) curve, the diagnostic and predictive value of D4Z4 methylation. Moreover, we performed DNA methylation analysis in selected large families with reduced penetrance characterized by the co-presence of subjects carriers of one D4Z4 reduced allele with no signs of disease or presenting the classic FSHD clinical phenotype. We observed a wide variability in the D4Z4 methylation levels among index cases revealing no association with clinical manifestation or disease severity. By extending the analysis to family members, we revealed the low predictive value of D4Z4 methylation in detecting the affected condition. In view of the variability in D4Z4 methylation profiles observed in our large cohort, we conclude that D4Z4 methylation does not mirror the clinical expression of FSHD. We recommend that measurement of this epigenetic mark must be interpreted with caution in clinical practice.
机译:面肩肱型肌营养不良症(FSHD)的特征是不完全外显和家族内临床变异性。该疾病与4q35处D4Z4重复元件的遗传和表观遗传特征有关。最近,D4Z4亚甲基化已被提出作为FSHD诊断中的可靠标记。我们利用了FSHD的意大利注册表,其中FSHD家族使用临床综合评价表(CCEF)进行了分类。总共选择了122个显示经典FSHD表型(CCEF,A类)的索引病例和110个亲属,以接受者工作特征(ROC)曲线,D4Z4甲基化的诊断和预测价值进行测试。此外,我们在selected毛减少的选定大家族中进行了DNA甲基化分析,其特征是同时存在一个D4Z4减少等位基因的受试者携带者,而没有疾病迹象或表现出经典的FSHD临床表型。我们观察到索引病例之间D4Z4甲基化水平存在很大差异,表明与临床表现或疾病严重程度无关。通过将分析扩展到家庭成员,我们揭示了D4Z4甲基化在检测患病情况中的低预测价值。考虑到在我们的大型队列研究中观察到的D4Z4甲基化谱的变异性,我们得出结论,D4Z4甲基化不能反映FSHD的临床表达。我们建议在临床实践中必须谨慎解释对这种表观遗传标记的测量。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号